Teva to lay off 250 at API unit as search for new owner drags on: report

Israeli pharma giant Teva lays off 250 of its Israel-based staff

Teva cuts 250 Israel staff (38% of TAPI) as $1.5B sale fails due to East Asian pressure on generic-drug margins. The move signals pharma's forced pivot from low-margin generics to biosimilars and oligonucleotide innovation amid industry consolidation.